Viral vector gene therapies are an exciting new approach to treating serious conditions, however, they pose unique development and manufacturing challenges. Vibalogics’ viral vector gene therapy manufacturing service is founded on our team’s decades of experience in the field.
YOUR GENE THERAPY EXPERTS
Gene therapy vectors for in- or ex-vivo applications
Utilized across multiple in-vivo and ex-vivo applications, viral vectors are an advanced tool of drug developers to deliver genetic information into a host cell paving the way for therapeutic potential previously unseen. Energized by the curative potential of these modalities and a tailwind of commercial success, there is a current intense focus in market on gene therapy development and manufacturing. Our gene therapy services are set up to service customer programs in a variety of production methodologies. To simplify tech transfer and minimize time-to-market for your therapy, we offer early-to-late-stage clinical- and commercial-manufacturing capability, providing seamless end-to-end project support and small- to large-scale gene therapy production.
Gene Therapy Experience
- Adenovirus (Ad)
- Adeno-Associated Virus (AAV)
- Herpes Simplex Virus (HSV)
- Plasmid transfection processes
- Helper virus infection / transduction processes
- Producer cell line systems
- Platform manufacturing unit operations established
- Platform analytical methods for quality control
Looking for something different?
Vibalogics can assist you through a comprehensive service portfolio – ensuring success of your virotherapy, beginning with process development and technical transfer feasibility, through cGMP production and validation.
Drug Substance & Drug Product
Single-use production technologies, adherent and suspension processes, and non-aseptic or aseptic conditions from 50-2000L scale.
Method development and transfer services span characterization and quality control assays for identity, purity, potency, titer, and safety.
Top Tips in Selecting your Viral Vector Partner
From cutting-edge therapies for deadly cancers, to developing effective vaccines, the viral vector space is an exciting place to be. However, viral vector development poses unique challenges that must be addressed in order for your innovation to reach the market.